Kurma Partners closes growth fund at 160m
French venture capital expert Kurma Partners has closed its Growth Opportunities Fund at 160m and targets a final closing at 250m.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1300 entries already.
Entries by Thomas Gabrielczyk
mRNA for Africa
/in News/by Thomas GabrielczykModerna will build its first mRNA production facility in Kenya, investing up to US$500m.
Epsilogen raise £30.75m in Series B financing
/in News/by Thomas GabrielczykIgE cancer antibody specialist Epsilogen Ltd has closed a £30.75m round led by Novartis Venture Fund to advance Phase Ib studies with MOv18 IgE in platinum-resistant ovarian cancer.
Syndesi swallowed by Abbvie
/in News/by Thomas GabrielczykAbbVie has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie’s neuroscience portfolio.
Meletios Therapeutics licences antiviral patent
/in News/by Thomas GabrielczykParis-based Meletios Therapeutics SA has licenced know-how from the Institut Pasteur for the development of a new class of antivirals-
TargED Biopharmaceuticals BV raises 39m in Series A financing
/in News/by Thomas GabrielczykTargED Biopharmaceuticals will use 39m from a Series A financing to bring its thrombolytic treatment to patients.
Finnish VTT spin-out Onego Bio Ltd raises 10m
/in News/by Thomas GabrielczykThe cellular agriculture spin-off Onego Bio Ltd has been seeded with 10m to use its Trichoderma platform to establish an animal-free egg protein production.
Moderna wants to extent its European footprint
/in News/by Thomas GabrielczykThe former mRNA start-up Moderna Inc is set to expand its commercial network in six European nations to become a gobally active vaccine company.
Centauri Therapeutics starting with £24m financing
/in News/by Thomas GabrielczykAntimicrobial resistance specialist Centauri Therapeutics Ltd has closed a £24m Series A round to identify novel therapeutic candidates using the Alphamer technology.
Curve Therapeutics in US$1.7bn deal with MSD
/in News/by Thomas GabrielczykCurve Therapeutics has inked a contract with US pharma giant Merck & Co. (MSD) to screen novel small molecule drug candidates against five MSD targets.